PMID- 18593272
OWN - NLM
STAT- MEDLINE
DCOM- 20080729
LR  - 20080702
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 109
IP  - 1
DP  - 2008 Jul
TI  - Monocyte chemoattractant protein-1 predicts outcome and vasospasm following 
      aneurysmal subarachnoid hemorrhage.
PG  - 38-43
LID - 10.3171/JNS/2008/109/7/0038 [doi]
AB  - OBJECT: Despite efforts to elucidate both the molecular mechanism and the 
      clinical predictors of vasospasm after aneurysmal subarachnoid hemorrhage (ASAH), 
      its pathogenesis remains unclear. Monocyte chemoattractant protein-1 (MCP-1) is a 
      chemokine that has been firmly implicated in the pathophysiology of vasospasm and 
      in neural tissue injury following focal ischemia in both animal models and human 
      studies. The authors hypothesized that MCP-1 would be found in increased 
      concentrations in the blood and cerebrospinal fluid (CSF) of patients with ASAH 
      and would correlate with both outcome and the occurrence of vasospasm. METHODS: 
      Seventy-seven patients who presented with ASAH were prospectively enrolled in 
      this study between July 2001 and May 2002. Using an enzyme-linked immunosorbent 
      assay, MCP-1 levels were measured in serum daily and in CSF when available. The 
      mean serum and CSF MCP-1 concentrations were calculated for each patient 
      throughout the entire hospital stay. Neurological outcome was evaluated at 
      discharge or 14 days posthemorrhage using the modified Rankin Scale. Vasospasm 
      was evaluated on angiography. RESULTS: The serum MCP-1 concentrations correlated 
      with negative outcome such that a 10% increase in concentration predicted a 25% 
      increase in the probability of a poor outcome, whereas the serum MCP-1 levels did 
      not correlate with vasospasm. Concentrations of MCP-1 in the CSF, however, proved 
      to be significantly higher in patients with angiographically demonstrated 
      vasospasm. CONCLUSIONS: These findings suggest a role for MCP-1 in neurological 
      injury and imply that it may act as a biomarker of poor outcome in the serum and 
      of vasospasm in the CSF.
FAU - Kim, Grace H
AU  - Kim GH
AD  - Department of Neurological Surgery, Columbia University, New York, New York 
      10032, USA. ghkim9@yahoo.com
FAU - Kellner, Christopher P
AU  - Kellner CP
FAU - Hahn, David K
AU  - Hahn DK
FAU - Desantis, Brianna M
AU  - Desantis BM
FAU - Musabbir, Muhith
AU  - Musabbir M
FAU - Starke, Robert M
AU  - Starke RM
FAU - Rynkowski, Michal
AU  - Rynkowski M
FAU - Komotar, Ricardo J
AU  - Komotar RJ
FAU - Otten, Marc L
AU  - Otten ML
FAU - Sciacca, Robert
AU  - Sciacca R
FAU - Schmidt, J Michael
AU  - Schmidt JM
FAU - Mayer, Stephan A
AU  - Mayer SA
FAU - Connolly, E Sander Jr
AU  - Connolly ES Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood/*cerebrospinal fluid
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Intracranial Aneurysm/complications/*metabolism/therapy
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Severity of Illness Index
MH  - Subarachnoid Hemorrhage/complications/*metabolism/therapy
MH  - Treatment Outcome
MH  - Vasospasm, Intracranial/blood/cerebrospinal fluid/*etiology
EDAT- 2008/07/03 09:00
MHDA- 2008/07/30 09:00
CRDT- 2008/07/03 09:00
PHST- 2008/07/03 09:00 [pubmed]
PHST- 2008/07/30 09:00 [medline]
PHST- 2008/07/03 09:00 [entrez]
AID - 10.3171/JNS/2008/109/7/0038 [doi]
PST - ppublish
SO  - J Neurosurg. 2008 Jul;109(1):38-43. doi: 10.3171/JNS/2008/109/7/0038.